At least one U.S. Congressional committee will hold a public hearing specifically addressing FDA policy on ibogaine (including access, scheduling, or clinical trial pathways) before March 31, 2027.

A U.S. Congressional committee will hold a public hearing asking the FDA to defend why Americans can't easily access ibogaine treatment, especially for veterans with PTSD and addiction. This matters because veterans are dying while accessing ibogaine overseas, creating political pressure for Congress to investigate regulatory roadblocks.

Veterans dying from PTSD and opioid use disorder while ibogaine shows efficacy in foreign clinics is a potent political narrative. The Senate Veterans Affairs Committee and House Armed Services Committee have previously shown willingness to engage on psychedelic treatment access. Congressional hearings follow sustained media coverage; this story has documented deaths, military demographics, and an easily communicable claim of regulatory obstruction. Resolvable via public Congressional record. Confidence reflects genuine uncertainty about committee scheduling priorities.